()
 
 

Overview

Immunicon Corporation is developing and commercializing proprietary cell- and molecular-based human diagnostic and life science research products with an initial focus on cancer disease management. Immunicon has developed platform technologies for selection and analysis of rare cells in blood, such as circulating tumor cells and circulating endothelial cells that are important in many diseases and biological processes. Immunicon's products and underlying technology platforms also have application in the clinical development of cancer drugs and in cancer research and may have applications in other fields of medicine, such as cardiovascular and infectious diseases. For more information, please visit www.immunicon.com


Contact Information

3401 Masons Mill Road
Suite 100
Huntingdon Valley, PA 19006

tel: 215-830-0777
fax:
http://www.immunicon.com

,  



Investor Relations



tel:
fax:




Stock

Exchange: NASDAQ
Industry: Scientific & Technical Instruments
Market Cap: $8.3M




 
The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.